Andrew is a clinician, clinical researcher, founding medical journal editor and author.
He has been active at the Royal Society of Medicine for many years and served as President of the section of Vascular Lipid & Metabolic Medicine from 2022-4.
Andrew graduated from the University of Birmingham and specialised in general internal medicine, diabetes & endocrinology. He is also accredited as a clinical specialist by the European Society of Hypertension.
Following an MD thesis on insulin resistance his postgraduate experience included fellowships at the University of New Mexico School of Medicine and the University of California San Diego. Andrew’s PhD in biomedical science was awarded on his published record of cardiometabolic translational research.
On completing his clinical training Andrew was appointed Consultant Physician and Clinical Senior Lecturer at University Hospital Southampton. He later returned to San Diego to develop new therapies for cardiometabolic disorders as Senior Director of an independent clinical research institute. Andrew was subsequently invited to join the University of Buckingham as Professor of Endocrinology & Metabolism and Director of the Clore Life Sciences laboratory and the Translational Research Institute.
Currently, Andrew holds visiting chairs in the School of Life Course & Population Health Sciences at King’s College London and at the Institute for Cardiovascular & Metabolic Research at the University of Reading. In 2025, he was awarded a visiting Fellowship at the transdisciplinary Santa Fe Institute for complex systems science to study the role of insulin in health and disease.
The Faculty of Pharmaceutical Medicine of the Royal College of Physicians and the Royal College of Pathologists have both conferred honorary lifetime Fellowships on Andrew in recognition of his contributions to pharmaceutical medicine and clinical biochemistry, respectively.
With colleagues in academia and the life sciences Andrew is exploring machine learning for personalised management of cardiometabolic disease. In parallel, he has convened an international alliance to improve multidisciplinary education and training in cardiometabolic medicine. As a Fellow of the Royal Society of Arts he also leads a collaboration exploring design applied to health.